57690-96-7

Upstream product

• 10276-09-2 2,2-dimethyl-but-3-enoic acid 
• 115-18-4 2-methyl-3-buten-2-ol 
• 124-38-9 carbon dioxide 
• 58544-20-0 ethyl 2,2-dimethyl-3-butenoate 
• 7505-94-4 ethyl 3-hydroxy-2,2-dimethylbutanoate 
• 316148-56-8 ethyl 2,2-dimethyl-3-(4-toluenesulfonyloxy)butanoate 
• 38923-57-8 methyl 2,2-dimethyl-3-oxobutanoate 
• 19757-86-9 methyl 2,2-dimethyl-3-pentenoate 
• 69737-23-1 methyl 3-hydroxy-2,2-dimethylbutanoate 
• 29269-83-8 3-hydroxy-2,2-dimethyl-butyric acid 
• 503-60-6 3,3-dimethyl-allyl chloride 
• 2190-48-9 3-chloro-3-methyl-1-butene 
• 78-79-5 isoprene 
• 714273-85-5 2,2-dimethyl-3-(toluene-4-sulfonyloxy)-butyric acid methyl ester 

Downstream Products

• 7472-48-2 2,2-dimethyl-but-3-enoic acid amide 
• 125880-13-9 1-(2',2'-Dimethyl-3'-butenoyl)piperidine-2-thione 
• 42507-33-5 5-isopropyliden-2,3-dimethyl-2-cyclopenten-1-on 
• 66248-79-1 ethyl 4,4-dimethyl-3-oxo-hex-5-enoate 
• 211696-55-8 2,2-Dimethyl-but-3-enoic acid (2-chloro-benzyl)-hydroxy-amide 
• 915969-37-8 2-(2,2-dimethyl-but-3-enoylamino)-benzamide 
• 915969-48-1 2-[4-(2-diphenylphosphanylnaphthalen-1-yl)quinazolin-2-yl]-2-methylpropionitrile 
• 316148-60-4 5-(1,1-dimethyl-2-propenyl)imidazole-4-carbaldehyde 
• 316148-57-9 ethyl 2-chloro-3-oxo-4,4-dimethyl-5-hexenoate 
• 316148-59-1 (5-(1,1-dimethyl-2-propenyl)imidazole-4-yl)methanol 
• 316148-58-0 ethyl 5-(1,1-dimethyl-2-propenyl)imidazole-4-carboxylate 

Relevant academic research and scientific papers

Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment

A new series of C-phenyl D-glucitol derivatives was designed and synthesized, and their SGLT1 inhibitory potency and absorbability were evaluated. We also investigated whether kidney drug retention could be avoided by creating molecules with different excretion pathways. To achieve a class of molecules with low absorption and that were excreted in bile, optimized synthesis was performed to bring the ClogP value and the topological polar surface area to within the appropriate ranges. Compounds 34d and 34j were poorly absorbed, but the absorbed compounds were mainly excreted in bile. Thus, smaller amounts of persistent residue in the kidneys were observed. Since 34d exerted a glucose-lowering effect at a dose of 0.3 mg/kg (p.o.) in SD rats, this compound (SGL5213) could be a clinical candidate for the treatment of type 2 diabetes.

Alkene hydrofunctionalization using hydroxamic acids: A radical-mediated approach to alkene hydration

A radical-mediated approach to alkene hydration is described. The present strategy capitalizes on the unique radical reactivity of hydroxamic acids, which are capable of functioning as both synthetically useful oxygen-centered radical species and suitable hydrogen atom-based donors. This reaction manifold has been applied to both alkene hydrations and tandem alkene-alkene carbocyclization processes.

4-ISOPROPYL-6-METHOXYPHENYL GLUCITOL COMPOUND

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided:

SGC STIMULATORS

Compounds of Formula (I) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Neutral nazarov-type cyclization catalyzed by palladium(0)

Joining the circle: The first Pd0 catalyzed Nazarov-type cyclization of diketoesters (see scheme) proceeds in 70 % to 95 % yield under strictly neutral pH conditions. Aryl substitution of the diketoesters is not required, so the reaction shows great versatility and can also proceed with aliphatic substrates. Copyright

ANALOGS OF DEHYDROPHENYLAHISTINS

Analogs of dehydrophenylahistins are disclosed as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.

Metal-free oxyaminations of alkenes using hydroxamic acids

A radical-mediated approach to metal-free alkene oxyamination is described. This method capitalizes on the unique reactivity of the amidoxyl radical in alkene additions to furnish a general difunctionalization using simple diisopropyl azodicarboxylate (DIAD) as a radical trap. This protocol capitalizes on the intramolecular nature of the process, providing single regioisomers in all cases. Difunctionalizations of cyclic alkenes provide trans oxyamination products inaccessible using current methods with high levels of stereoselectivity, complementing cis-selective oxyamination processes.

Metal-free, aerobic dioxygenation of alkenes using hydroxamic acids

(Chemical equation presented) One dioxygenation please, hold the metal: In the presence of either oxygen or air as the sole oxidant and external oxygen atom source, a variety of unsaturated hydroxamic acids afford cyclic hydroxamates that are readily converted into 1,2-diols, with the potential for high levels of reaction stereocontrol.

ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE

Compounds represented by the following structure (II) are disclosed: as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.

Synthesis and application of quinazoline-oxazoline-containing (Quinazox) ligands

(Chemical Equation Presented) A practical synthesis of potentially tridentate P,N,N-ligands containing two stereogenic elements incorporated into the axially chiral Quinazolinap and centrally chiral 2-oxazoline subunits is reported. The application of these novel hybrid ligands in Pd(0)-catalyzed asymmetric allylic alkylation revealed the matched and mismatched diastereomer, dominant stereogenic element, as well as the effect of the oxazoline R substituent on the level of enantioselectivity (ee's up to 81%).